Skip to Content
Home > Services > Cancer > Clinical Research Trials > Clinical Trial Search > Detail
Back to Results
This randomized phase II trial studies how well dabrafenib and trametinib work in treating patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Patients with known history or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR) are not eligible:
Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as:
Patients with known human immunodeficiency virus (HIV) may be eligible providing they meet the following additional criteria:
No current antiretroviral therapy
864-560-1019 or 864-560-6812
Thank you for your feedback!
Get the latest news on the health topics that matter most to you.
© 2019 Spartanburg Regional Healthcare System. All Rights Reserved.